The DOI matches its Crossref record; 265 of the 265 references it cites were found in a registry or an index.
Nanomaterials for cancer immunotherapy
Open accessAbstract
Cancer immunotherapy is quickly growing to be the fourth most important cancer therapy, after surgery, radiation therapy, and chemotherapy. Immunotherapy is the most promising cancer management strategy because it orchestrates the body’s own immune system to target and eradicate cancer cells, which may result in durable antitumor responses and reduce metastasis and recurrence more than traditional treatments. Nanomaterials hold great promise in further improving the efficiency of cancer immunotherapy - in many cases, they are even necessary for effective delivery. In this review, we briefly summarize the basic principles of cancer immunotherapy and explain why and where to apply nanomaterials in cancer immunotherapy, with special emphasis on cancer vaccines and tumor microenvironment modulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–265 of 265
Desar, I. M. E., Jacobs, J. F. M., Hulsbergen‐vandeKaa, C. A., Oyen, W. J. G., Mulders, P., van der Graaf, W. T. A., Adema, G. J., van Herpen, C. M. L., & de Vries, I. J. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25674 · Cited by 146
Kourtis, I. C., Hirosue, S., de Titta, A., Kontos, S., Stegmann, T., Hubbell, J. A., & Swartz, M. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061646 · Cited by 143
Belizaire, R., & Unanue, E. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908583106 · Cited by 143
Xu, L., Liu, Y., Chen, Z., Li, W., Liu, Y., Wang, L., Ma, L., Shao, Y., Zhao, Y., & Chen, C. (2013) · Advanced Materials · doi:10.1002/adma.201300583 · Cited by 142
Yu, H., Tang, Z., Zhang, D., Song, W., Zhang, Y., Yang, Y., Ahmad, Z., & Chen, X. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.022 · Cited by 138
Self-citationSong, W., Tang, Z., Zhang, D., Zhang, Y., Yu, H., Li, M., Lv, S., Sun, H. Y., Deng, M., & Chen, X. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.018 · Cited by 135
Self-citationFunctionalized carbon nanotubes as immunomodulator systems
Pescatori, M., Bedognetti, D., Venturelli, E., Ménard‐Moyon, C., Bernardini, C., Muresu, E., Piana, A. F., Maida, G., Manetti, R., Sgarrella, F., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.052 · Cited by 135
The present status and future prospects of peptide-based cancer vaccines
Hirayama, M., & Nishimura, Y. (2016) · International Immunology · doi:10.1093/intimm/dxw027 · Cited by 135
Nagai, T., Tanaka, M., Tsuneyoshi, Y., Xu, B., Michie, S. A., Hasui, K., Hirano, H., Arita, K., & Matsuyama, T. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0667-x · Cited by 134
Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer
Miao, L., Li, J., Liu, Q., Feng, R., Das, M., Lin, C. M., Goodwin, T. J., Dorosheva, O., Liu, R., & Huang, L. (2017) · ACS Nano · doi:10.1021/acsnano.7b01786 · Cited by 134
Self-citationA simple but effective cancer vaccine consisting of an antigen and a cationic lipid
Chen, W., Yan, W., & Huang, L. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0390-4 · Cited by 127
Self-citationAhmad, R., Raina, D., Meyer, C., & Kufe, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3036 · Cited by 120 · cited 1×
“(3) inhibition of the function of MDSCs, using phosphodiesterase-5 (PDE-5) inhibitors [212], COX2/PGE2 inhibitors [213, 214], JAK1/STAT3 inhibitors like bardoxolone methyl (CDDO-Me) [215], etc.”
MethodLei, C., Liu, P., Chen, B., Mao, Y., Engelmann, H. E., Shin, Y., Jaffar, J., Hellström, I., Liu, J., & Hellström, K. E. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102414t · Cited by 119
A Highly Efficient Synthetic Vector: Nonhydrodynamic Delivery of DNA to Hepatocyte Nucleiin Vivo
Hu, Y., Haynes, M. T., Wang, Y., Liu, F., & Huang, L. (2013) · ACS Nano · doi:10.1021/nn4012384 · Cited by 119
Self-citationImmunomodulation of Nanoparticles in Nanomedicine Applications
Jiao, Q., Li, L., Mu, Q., & Zhang, Q. (2014) · BioMed Research International · doi:10.1155/2014/426028 · Cited by 118
Engineered materials for cancer immunotherapy
Cheung, A. S., & Mooney, D. J. (2015) · Nano Today · doi:10.1016/j.nantod.2015.06.007 · Cited by 111
In VivoTargeting of Intratumor Regulatory T Cells Using PEG-Modified Single-Walled Carbon Nanotubes
Sacchetti, C., Rapini, N., Magrini, A., Cirelli, E., Stefano Bellucci, A., Mattei, M., Rosato, N., Bottini, N., & Bottini, M. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400070q · Cited by 98
Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy?
Fontana, F., Liu, D., Hirvonen, J. J., & Santos, H. A. (2016) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1421 · Cited by 98
Cross-talk within the tumor microenvironment mediates Th2-type inflammation in pancreatic cancer
Protti, M. P., & Monte, L. B. D. (2012) · OncoImmunology · doi:10.4161/onci.1.1.17939 · Cited by 97
Cancer vaccine adjuvants – recent clinical progress and future perspectives
Banday, A. H., Jeelani, S., & Hruby, V. J. (2014) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2014.971963 · Cited by 96
Cruz, L. J., Rueda, F., Cordobilla, B., Simón‐Gracia, L., Hosta‐Rigau, L., Alberício, F., & Domingo, J. C. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100178k · Cited by 96
Xiang, S. D., Selomulya, C., Ho, J., Apostolopoulos, V., & Plebanski, M. (2010) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.88 · Cited by 93
Orecchioni, M., Jasim, D. A., Pescatori, M., Manetti, R., Fozza, C., Sgarrella, F., Bedognetti, D., Bianco, A., Kostarelos, K., & Delogu, L. G. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500606 · Cited by 92
Adapting Cancer Immunotherapy Models for the Real World
Klevorn, L. E., & Teague, R. M. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.03.010 · Cited by 91
Micro- and nanoparticulates for DNA vaccine delivery
Farris, E., Brown, D. M., Ramer‐Tait, A. E., & Pannier, A. K. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216643771 · Cited by 90
Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy.
DeLong, P. A., Tanaka, T. N., Kruklitis, R. J., Henry, A. C., Kapoor, V., Kaiser, L. R., Sterman, D. H., & Albelda, S. Μ. (2003) · PubMed · Cited by 89
Luo, Z., Li, P., Deng, J., Gao, N., Zhang, Y., Pan, H., Liu, L., Wang, C., Cai, L., & Ma, Y. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.027 · Cited by 88
Stable cationic microparticles for enhanced model antigen delivery to dendritic cells
Wischke, C., Borchert, H., Zimmermann, J., Siebenbrodt, I., & Lorenzen, D. R. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.06.020 · Cited by 87
Challenges facing adjuvants for cancer immunotherapy
Mesa, C., & Fernandez, L. E. (2004) · Immunology and Cell Biology · doi:10.1111/j.0818-9641.2004.01279.x · Cited by 86
Kretz-Rommel, A., Qin, F., Dakappagari, N. K., Torensma, R., Faas, S. J., Wu, D., & Bowdish, K. S. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318135472c · Cited by 84
Hengesbach, L. M., & Hoag, K. A. (2004) · Journal of Nutrition · doi:10.1093/jn/134.10.2653 · Cited by 83
Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities
Cousin, S., & Italiano, A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2569 · Cited by 83
Zhao, Y., Huo, M., Xu, Z., Wang, Y., & Huang, L. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.07.053 · Cited by 80
Self-citationLocal and transient gene expression primes the liver to resist cancer metastasis
Goodwin, T. J., Zhou, Y., Musetti, S., Liu, R., & Huang, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2306 · Cited by 80
Self-citationEnantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine
Vasievich, E. A., Chen, W., & Huang, L. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-0970-1 · Cited by 73
Self-citationLü, P., Yu, B., & Xu, J. (2012) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1219 · Cited by 73
Chen, M., Ouyang, H., Zhou, S., Li, J., & Ye, Y. (2014) · Cellular Immunology · doi:10.1016/j.cellimm.2014.01.003 · Cited by 71
Targeting the Neonatal Fc Receptor for Antigen Delivery Using Engineered Fc Fragments
Mi, W., Wanjie, S., Lo, S., Gan, Z., Pickl-Herk, B., Ober, R. J., & Ward, E. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.11.7550 · Cited by 71
From Immunotoxicity to Nanotherapy: The Effects of Nanomaterials on the Immune System
Smith, M. J., Brown, J. M., Zamboni, W. C., & Walker, N. J. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu005 · Cited by 70
Goodwin, T. J., & Huang, L. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.067 · Cited by 70
Self-citationInduction of Cytotoxic T-Lymphocytes and Antitumor Activity by a Liposomal Lipopeptide Vaccine
Chen, W., & Huang, L. (2008) · Molecular Pharmaceutics · doi:10.1021/mp700126c · Cited by 68
Self-citationsiRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions
Iwamura, K., Kato, T., Miyahara, Y., Naota, H., Mineno, J., Ikeda, H., & Shiku, H. (2011) · Gene Therapy · doi:10.1038/gt.2011.185 · Cited by 68
Lim, Y. T., Song, C., & Noh, Y. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s110796 · Cited by 67
Garçon, N., Leroux-Roels, G. G., & Cheng, W. (2011) · Perspectives in Vaccinology · doi:10.1016/j.pervac.2011.05.004 · Cited by 67
Rao, A., Taylor, J. L., Chi-Sabins, N., Kawabe, M., Gooding, W. E., & Storkus, W. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0538 · Cited by 62
New strategies for cancer immunotherapy: targeting regulatory T cells
Finotello, F., & Trajanoski, Z. (2017) · Genome Medicine · doi:10.1186/s13073-017-0402-8 · Cited by 62
Makkouk, A., Joshi, V. B., Wongrakpanich, A., Lemke-Miltner, C. D., Gross, B., Salem, A. K., & Weiner, G. J. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9676-6 · Cited by 59
Strugnell, R. A., Zepp, F., Cunningham, A. L., & Tantawichien, T. (2011) · Perspectives in Vaccinology · doi:10.1016/j.pervac.2011.05.003 · Cited by 58
Wiers, K. M., Lathers, D. M. R., Wright, M. A., & Young, M. R. (2000) · Journal of Immunotherapy · doi:10.1097/00002371-200001000-00014 · Cited by 53
Ramishetti, S., Garu, A., Moku, G., Agawane, S. B., & Chaudhuri, A. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.05.006 · Cited by 52
Matijevic, M., Hedley, M. L., Urban, R. G., Chicz, R. M., Lajoie, C., & Luby, T. M. (2011) · Cellular Immunology · doi:10.1016/j.cellimm.2011.04.005 · Cited by 51
Amorphous silica nanoparticles enhance cross-presentation in murine dendritic cells
Hirai, T., Yoshioka, Y., Takahashi, H., Ichihashi, K.-I., Yoshida, T., Tochigi, S., Nagano, K., Abe, Y., Kamada, H., Tsunoda, S., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.09.095 · Cited by 50
Gross, B., Wongrakpanich, A., Francis, M. B., Salem, A. K., & Norian, L. A. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9662-z · Cited by 49
Roeven, M. W. H., Hobo, W. A., van der Voort, R., Fredrix, H., Norde, W. J., Teijgeler, K., Ruiters, M. H. J., Schaap, N. P., & Dolstra, H. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000071 · Cited by 47
Liu, G. W., Livesay, B. R., Kacherovsky, N. A., Cieslewicz, M., Lutz, E. A., Waalkes, A., Jensen, M. C., Salipante, S. J., & Pun, S. H. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00344 · Cited by 46
Chakraborty, P., Chatterjee, S., Ganguly, A., Saha, P., Adhikary, A., Das, T., Chatterjee, M., & Choudhuri, S. K. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0611287 · Cited by 41
Editorial: PGE2-producing MDSC: a role in tumor progression?
Serafini, P. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0510303 · Cited by 40
Barichello, J. M., Ishida, T., & Kiwada, H. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-360-2_32 · Cited by 32
Li, P., Chen, S., Jiang, Y., Jiang, J., Zhang, Z., & Sun, X. (2013) · Nanotechnology · doi:10.1088/0957-4484/24/29/295101 · Cited by 32
Umthong, S., Buaklin, A., Jacquet, A., Sangjun, N., Kerdkaew, R., Patarakul, K., & Palaga, T. (2015) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1408.08007 · Cited by 32
Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors
Zulfiqar, B., Mahroo, A., Nasir, K., Farooq, R. K., Jalal, N., Rashid, M. U., & Asghar, K. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s119362 · Cited by 22
Barbon, C. M., Baker, L., Lajoie, C., Ramstedt, U., Hedley, M. L., & Luby, T. M. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.09.078 · Cited by 19
Targeting Treg Cells In Situ: Emerging Expansion Strategies for (CD4+CD25+) Regulatory T Cells
Shatry, A. M., Chirinos, J., Gorin, M. A., Jones, M., & Levy, R. B. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.06.009 · Cited by 13
Holtzhausen, A., Zhao, F. L., Evans, K. S., & Hanks, B. A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00438 · Cited by 12
Insights on Peptide Vaccines in Cancer Immunotherapy
Tsang, K. Y., Jochéms, C., & Schlom, J. (2015) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-21167-1_1 · Cited by 5
Cited by
Reactive Oxygen Species (ROS)-Based Nanomedicine
Yang, B., Chen, Y., & Shi, J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00626 · Cited by 2,443
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,155
Yang, B., Chen, Y., & Shi, J. (2019) · Advanced Materials · doi:10.1002/adma.201901778 · Cited by 601
Porphyrin‐Based Metal–Organic Frameworks for Biomedical Applications
Chen, J., Zhu, Y., & Kaskel, S. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.201909880 · Cited by 597
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2021) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 450
Metadata
- Authors
- Song, W., Musetti, S. N., & Huang, L.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 148
- Pages
- 16-30
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2755360248
- Cited by
- 281
- References
- 265
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.